Efmitermant alfa clinical trials
Also written ACE-083.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2014
How each study uses efmitermant alfa is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- ACE-083
- 4
Studies by the year they started
4 studies that test it; most in 2014 (1)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA (4)
Studies
Open first, then newest update. How each study uses efmitermant alfa is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD)TerminatedPhase 2Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USANCT02927080Written as ACE-083
- Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) and Charcot-Marie Tooth (CMT) Disease Types 1 and X (CMT1 and CMTX)TerminatedPhase 2Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USANCT03943290Written as ACE-083
- Study of ACE-083 in Patients With Charcot-Marie-Tooth DiseaseTerminatedPhase 2Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USANCT03124459Written as ACE-083
- Phase 1 Study of ACE-083 in Healthy SubjectsCompletedPhase 1Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USANCT02257489Written as ACE-083
Codes
What other systems call efmitermant alfa · ClinicalTrials.gg INT015015
- UNII (FDA) 566QNS333VEFMITERMANT ALFAOne source FDA
- NCI Thesaurus C166821Efmitermant AlfaOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 566QNS333V | EFMITERMANT ALFA | One source FDA |
| NCI Thesaurus | C166821 | Efmitermant Alfa | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.